Kaplan 1996.

Methods	Description: random‐assignment, placebo‐controlled, crossover, fixed dose, double‐blind, 2 week washout period BLINDING Participants: Yes Assessors: Unclear Administrators: Yes (self administered) ALLOCATION CONCEALMENT Method: Identical capsules used for medication and placebo RANDOMISATION Method: pre‐arranged random code
Participants	SAMPLE Description: 17 DSM‐III‐R PTSD, 23% (3/13) combat‐related, mean age for OC: 39.7 year (25‐56), 62% male, duration of diagnosis for OC: 0.5‐28 years, no comorbid major depression, baseline severity on IES for OC: inositol (35.8) and placebo (34.9) SCREENING Primary diagnosis: No information Comorbidity: No information
Interventions	Description: inositol 12 g/d versus placebo x 4 weeks
Outcomes	IES , SCL‐90 (1 centre), HAM‐A, HAM‐D (other centre) (no distinction between primary and secondary outcomes) Data estimation: Completer values
Notes	INDUSTRY SUPPORT Industry funded: No information Medication provided by industry: No Any of the authors work for industry: No information ADDITIONAL INFORMATION Drop‐out rates: 4/17 (24%) Quality rating score: 13
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear